Article Text

PDF
Natalizumab and progressive multifocal leucoencephalopathy
  1. J R Berger
  1. Department of Neurology, University of Kentucky College of Medicine, Lexington, KY, USA
  1. Correspondence to:
    Dr J R Berger
    Department of Neurology, University of Kentucky College of Medicine, Kentucky Clinic L-445, 740 S Limestone Street, Lexington, KY 40536-0284, USA; jrbneuro{at}uky.edu

Abstract

Current data suggest that as many as 1 in 1000 treated individuals may develop progressive multifocal leucoencephalopathy (PML) in concert with the use of natalizumab. Natalizumab was withdrawn in early 2005. The present paper provides a comprehensive description of PML and reviews the role of natalizumab in the pathogenesis of PML. It is likely that use of drugs which cause specific perturbations of the immune system will be accompanied by similar rare infections. Thus researchers should be on the alert when using such agents in clinical trials.

  • AIDS, acquired immune deficiency syndrome
  • CNS, central nervous system
  • CSF, cerebrospinal fluid
  • HAART, highly active antiretroviral therapy
  • HIV, human immunodeficiency virus
  • JCV, JC virus
  • MS, multiple sclerosis
  • PML, progressive multifocal leucoencephalopathy
  • natalizumab
  • progressive multifocal leucoencephalopathy
  • demyelination
  • multiple sclerosis
  • monoclonal antibodies

Statistics from Altmetric.com

Footnotes

  • Competing interests: none declared

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.